Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.670
-0.040 (-2.34%)
At close: Aug 1, 2025, 4:00 PM
1.730
+0.060 (3.59%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.

In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus.

Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.

The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020.

Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Precigen, Inc.
Precigen logo
CountryUnited States
Founded1998
IndustryBiotechnology
SectorHealthcare
Employees143
CEOHelen Sabzevari

Contact Details

Address:
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
United States
Phone301 556 9900
Websiteprecigen.com

Stock Details

Ticker SymbolPGEN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001356090
CUSIP Number74017N105
ISIN NumberUS74017N1054
SIC Code2834

Key Executives

NamePosition
Dr. Helen Sabzevari MPH, Ph.D.President, Chief Executive Officer and Director
Randal J. Kirk J.D.Executive Chairman
Harry Thomasian Jr.Chief Financial Officer
Rutul R. ShahChief Operating Officer
Donald P. Lehr J.D., Ph.D.Chief Legal Officer and Corporate Secretary
Phil TennantChief Commercial Officer
Steven M. HarasymVice President and Head of Investor Relations
Rob RussellVice President and Head of Human Resources
Dr. Douglas E. Brough Ph.D.Senior Vice President and Head of Research
Dr. Bryan T. Butman Ph.D.Senior Vice President and Head of CMC

Latest SEC Filings

DateTypeTitle
Jun 30, 20258-KCurrent Report
May 16, 2025ARSFiling
May 16, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 16, 2025DEF 14AOther definitive proxy statements
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 6, 2025PRE 14AOther preliminary proxy statements
Apr 28, 202510-K/A[Amend] Annual report
Mar 19, 202510-KAnnual Report
Mar 19, 20258-KCurrent Report